Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (30)	1/25/1999 5:53:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 360

Thanks...the puzzle is starting to come together for me. I'll go back and read through the thread quickly to see what I find...but for now, another question:-) I know GLGC got a lot of tissue samples from Oncormed...but where are the compounds for screening coming from--do biotech companies subscribe to a service where a van from, say, Pharmacopia pulls up once a months with thousands of new molecules on which GLGC runs their assays? (did I even phrase that right!?) Also, does GLGC have a database of useful polymorphisms--apparently there are something like 5000 publicly-known SNPs--but I dont even know how many of those are outside of the genes which are actually expressed. I heard something about Iceland selling their genetic data for this reason, so I am guessing mutation data is valuable--the vcall recording did get one thing to sink into my head, that glgc beleives it can help stratify the composition of people in trials if leads do go clinical... and for that you have to know the SNPs, right? How all this happens from the flow-through-chip, to screening, to clinical trials is not at all obvious to me yet however. --Mike